XML 216 R13.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Investments | 12 Months Ended
--- | ---
Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract] |
Investments | Investments Available-for-sale securities The Company’s portfolio of available-for-sale marketable securities consists of the following:
| December 31, 2023
| Amortized Cost |  | Gross unrealized |  | Estimated Fair Value
(In thousands) |  | Gains |  | Losses |
Available-for-sale securities, current portion |  |  |  |  |  |  |
U.S. government securities | $ | 5,169 |  |  | $ | 1 |  |  | $ | — |  |  | $ | 5,170 |
Corporate debt securities | 9,673 |  |  | 5 |  |  | (4) |  |  | 9,674 |
Other debt securities | 1,443 |  |  | 1 |  |  | — |  |  | 1,444 |
Total short-term | 16,285 |  |  | 7 |  |  | (4) |  |  | 16,288 |
Available-for-sale securities, long-term |  |  |  |  |  |  |
Other debt securities | 545 |  |  | 3 |  |  | — |  |  | 548 |
Total available-for-sale securities | $ | 16,830 |  |  | $ | 10 |  |  | $ | (4) |  |  | $ | 16,836 |
(In thousands) | Amortized Cost |  | Estimated Fair Value
Due in one year or less | $ | 16,285 |  |  | $ | 16,288 |
Due after one year through five years | 545 |  |  | 548 |
Total | $ | 16,830 |  |  | $ | 16,836 |
There were no outstanding available-for-sale marketable securities as of December 31, 2022. As of December 31, 2023, none of our available-for-sale marketable securities exhibited risk of credit loss and therefore no allowance for credit losses was recorded. Equity investments The Company periodically invests in non-marketable equity securities of private companies without a readily determinable fair value to promote business and strategic objectives. The non-marketable equity securities are carried at cost minus impairment, if any, plus or minus changes resulting from observable process changes in orderly transactions for identical or similar investments of the same issuer. These securities included Series A-1 and A-2 Preferred Stock in iVexSol, Inc. with a fair value of $4.1 million as of December 31, 2023 and December 31, 2022, and Series E Preferred Stock in PanTHERA CryoSolutions, Inc. with a fair value of $995,000 as of December 31, 2023 and December 31, 2022.

X
- Definition The entire disclosure for investment. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//320/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Topic 321 -Publisher FASB -URI https://asc.fasb.org//321/tableOfContent Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Topic 325 -Publisher FASB -URI https://asc.fasb.org//325/tableOfContent + Details
Name: | us-gaap_InvestmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration